Here are the 424B prospectus supplements from Electra Therapeutics, Inc. (ETRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ETRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ETRA filings page.
Electra Therapeutics, Inc. (ETRA) is conducting an initial public offering of 23,333,334 shares of common stock at $15.00 per share, raising gross proceeds of $350.0 million and approximately $325.5 million in proceeds before expenses, with Nasdaq Global Select Market listing under the symbol ETRA. Underwriters have a 30‑day option to purchase up to 3,500,000 additional shares. Electra is a late clinical‑stage biopharmaceutical company developing precision medicines that target signal regulatory proteins (SIRP) to selectively deplete disease‑driving immune cells in immune‑mediated diseases and cancer. Lead candidate ipsoprubart is in a global Phase 2/3 registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH) after Phase 1b data showing 100% 8‑week overall survival and overall response in 12 frontline malignancy‑associated HLH patients; it has FDA Breakthrough Therapy and EMA PRIME designations. Second candidate ELA822 is in a Phase 1 trial in Europe targeting chronic T cell‑mediated diseases. The company has no approved products, reported a net loss of $62.0 million in 2025 and an accumulated deficit of $221.9 million as of June 30, 2026, and its auditors included a going‑concern explanatory paragraph; management expects existing cash plus IPO proceeds to fund operations into 2029.